Patel Anish 4
4 · Enliven Therapeutics, Inc. · Filed May 9, 2025
Insider Transaction Report
Form 4
Patel Anish
CHIEF OPERATING OFFICER
Transactions
- Sale
Common Stock
2025-05-07$19.40/sh−390$7,565→ 310,080 total(indirect: See footnote) - Sale
Common Stock
2025-05-07$18.30/sh−6,173$112,947→ 310,470 total(indirect: See footnote) - Sale
Common Stock
2025-05-07$19.87/sh−104$2,067→ 309,976 total(indirect: See footnote)
Footnotes (5)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust").
- [F2]This transaction was executed in multiple trades at prices ranging from $17.7781 to $18.7623. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]The shares are held by The Patel / Dong Family Trust.
- [F4]This transaction was executed in multiple trades at prices ranging from $18.7902 to $19.745. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F5]This transaction was executed in multiple trades at prices ranging from $19.80 to $19.97. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.